Not finding it? Sign in to also search OpenAlex live.
-
Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial
Antonio Maria Risitano, Austin Gladston Kulasekararaj, Alexander Roeth, Phillip Scheinberg, Yutaka Ueda, Eros Di Bona, +29 more
14citations -
Plain language summary: treatment of paroxysmal nocturnal hemoglobinuria with pegcetacoplan for 48 weeks (PEGASUS study)2024 Future Rare Diseases article Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +10 more
0citations -
Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria2025 British Journal of Clinical Pharmacology article Immunology and Microbiology Complement system in diseases Open access
Valérie F. Cosson, Rong Fu, Austin Gladston Kulasekararaj, Jun‐ichi Nishimura, Jens Panse, Alexander Röth, +14 more
10citations -
Real-world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across europe, the United States and Canada2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Koo Wilson, Sam Williamson, Susanna Libby, Peter Hillmen, David Dingli
0citations -
C1q binding to surface-bound IgG is stabilized by C1r 2 s 2 proteases2021 bioRxiv (Cold Spring Harbor Laboratory) preprint Immunology and Microbiology Complement system in diseases Open access
Seline A. Zwarthoff, Kevin Widmer, Annemarie Kuipers, Jürgen Strasser, Maartje Ruyken, Piet C. Aerts, +12 more
1citations -
P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT
Jeff Szer, Jens Panse, Austin Gladston Kulasekararaj, Monika Oliver, Bruno Fattizzo, Jun‐ichi Nishimura, +3 more
1citations -
C1q binding to surface-bound IgG is stabilized by C1r 2 s 2 proteases2021 Proceedings of the National Academy of Sciences article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent
Seline A. Zwarthoff, Kevin Widmer, Annemarie Kuipers, Jürgen Strasser, Maartje Ruyken, Piet C. Aerts, +13 more
62citations -
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent
Peter Hillmen, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +11 more
407citations -
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study2024 Advances in Therapy article Immunology and Microbiology Complement system in diseases Open access
Christopher Jordan Patriquin, Andrija D. Bogdanovic, Morag Griffin, Richard J. Kelly, Jaroslaw Pawel Maciejewski, Brian Patrick Mulherin, +9 more
20citations -
Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors2023 Clinical Pharmacology & Therapeutics article Immunology and Microbiology Complement system in diseases Open access
Jun‐ichi Nishimura, Antoine Soubret, Noriko Arase, Simon Buatois, Masaki Hotta, Jean‐Eric Charoin, +23 more
10citations -
Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis2023 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, Jun‐ichi Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
0citations -
Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study2022 Kidney International Reports article Immunology and Microbiology Complement system in diseases Open access
Romy N. Bouwmeester, Caroline Duineveld, Kioa Lente Wijnsma, Fréderike J. Bemelman, Joost W van der Heijden, Joanna A.E. van Wijk, +20 more
50citations -
An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial
Jun‐ichi Nishimura, Antoine Soubret, Simon Buatois, Jean‐Eric Charoin, Sasha Sreckovic, Christoph Marcus Bucher, +21 more
3citations -
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab2020 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access
Austin Gladston Kulasekararaj, Anita Hill, Saskia M. C. Langemeijer, Richard A. Wells, Fernando Ataúlfo González Fernández, Anna Gayà, +12 more
36citations -
Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study2022 Bone Marrow Transplantation article Immunology and Microbiology Complement system in diseases Open access
Peter Švec, Reem Elfeky, Jacques‐Emmanuel Galimard, Christine S. Higham, Arnaud Dalissier, Troy C. Quigg, +30 more
20citations